PMID- 36231528
OWN - NLM
STAT- MEDLINE
DCOM- 20221107
LR  - 20230118
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 19
IP  - 19
DP  - 2022 Sep 27
TI  - COVID-19 Vaccine in Inherited Metabolic Disorders Patients: A Cross-Sectional 
      Study on Rate of Acceptance, Safety Profile and Effect on Disease.
LID - 10.3390/ijerph191912227 [doi]
LID - 12227
AB  - BACKGROUND: Vaccines for COVID-19 have had a significant impact on the spread of 
      COVID-19 infection, reducing the incidence and mortality of the infection in 
      several countries. However, hesitancy toward this vaccine is a global health 
      issue for the general population The Vaccine acceptance rate among patients 
      affected with inherited metabolic disorders (IMD), as well as safety profile, has 
      not been described. METHODS: We conducted a cross-sectional study, based on a 
      telephone survey, investigating the COVID-19 vaccination rate, the incidence and 
      type of adverse effects (AEs), the reasons for vaccine refusal and the effects on 
      the underlying disease in a cohort of IMD patients followed at a single center 
      and invited directly to vaccination by specialistic team. RESULTS: Seventy-four 
      patients were included in the study, the median age was 23.4 years (min 12.1-max 
      61.7), 47% (n = 85) were females and 61% (107) were affected from impaired 
      metabolism of phenylalanine. By October 2021, 94% (n = 163) of them had received 
      at least one dose of the vaccine, which was, in 98% of cases, mRNA-based vaccine, 
      given at the referral hospital in 65% of cases. Overall, 72% of patients with IMD 
      reported AE to the vaccine: 60% after the first dose, 81% after the second. The 
      highest rate of adverse events at the first dose was reported in patients with 
      amino acids related disorders other than impaired phenylalanine metabolism 
      (PKU/HPA) (88%). For the second dose, the PKU/HPA group reported the highest rate 
      of AEs (89% of cases). There was no effect on the underlying disease or acute 
      decompensation after the vaccine. Eleven patients (6%) were not vaccinated 
      because they considered it dangerous. CONCLUSION: Among individuals with IMD, the 
      vaccination rate was high, the incidence and severity of AEs were comparable to 
      those in the general population with no effects on the disease. Direct contact 
      with the specialist medical team, has proven to reassure patients and effectively 
      contrast hesitancy.
FAU - Tummolo, Albina
AU  - Tummolo A
AUID- ORCID: 0000-0001-8823-8061
AD  - Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni 
      XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 
      Bari, Italy.
FAU - Dicintio, Annamaria
AU  - Dicintio A
AUID- ORCID: 0000-0003-0293-7465
AD  - Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni 
      XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 
      Bari, Italy.
FAU - Paterno, Giulia
AU  - Paterno G
AD  - Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni 
      XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 
      Bari, Italy.
FAU - Carella, Rosa
AU  - Carella R
AD  - Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni 
      XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 
      Bari, Italy.
FAU - Melpignano, Livio
AU  - Melpignano L
AD  - Medical Direction, Giovanni XXIII Children Hospital, Azienda 
      Ospedaliero-Universitaria Consorziale, 70126 Bari, Italy.
FAU - De Giovanni, Donatella
AU  - De Giovanni D
AD  - Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni 
      XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 
      Bari, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220927
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Young Adult
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/administration & dosage/adverse effects
MH  - Cross-Sectional Studies
MH  - *Metabolic Diseases/complications
MH  - RNA, Messenger
MH  - Vaccination/statistics & numerical data
MH  - Child
MH  - Adolescent
MH  - Middle Aged
MH  - Vaccination Refusal/statistics & numerical data
PMC - PMC9566545
OTO - NOTNLM
OT  - COVID-19
OT  - adverse effects
OT  - hereditary metabolic disorders
OT  - vaccine
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/18 06:00
PMCR- 2022/09/27
CRDT- 2022/10/14 01:58
PHST- 2022/07/31 00:00 [received]
PHST- 2022/09/15 00:00 [revised]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2022/10/14 01:58 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
PHST- 2022/09/27 00:00 [pmc-release]
AID - ijerph191912227 [pii]
AID - ijerph-19-12227 [pii]
AID - 10.3390/ijerph191912227 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2022 Sep 27;19(19):12227. doi: 
      10.3390/ijerph191912227.